MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Ophthalmology

Ophthalmology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Manual Marking Without Special Equipment Is Noninferior to Digital Guidance for Capsulorhexis Accuracy in Phacoemulsification
newsCataract

Manual Marking Without Special Equipment Is Noninferior to Digital Guidance for Capsulorhexis Accuracy in Phacoemulsification

By MedXY|Nov 25, 2025

A randomized noninferiority trial found that a device-free manual marking-assisted capsulorhexis (MMAC) produced capsulorhexis diameters and centration comparable to digital guidance (DGAC), supporting a low-cost, widely applicable techniqu

Foundation Models Narrow the Knowledge Gap in Ophthalmology but Struggle with Images
Superintelligenceophthalmology

Foundation Models Narrow the Knowledge Gap in Ophthalmology but Struggle with Images

By MedXY|Nov 25, 2025

Contemporary foundation models match experts on text-only ophthalmology exam questions but underperform on image-based items; targeted multimodal training and prospective validation are needed before clinical deployment.

Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue
Diabetes & Endocrinologygut microbiomeretinopathy đái tháo đường

Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue

By MedXY|Nov 9, 2025

A Gut 2025 study identifies microbially produced indole-3-propionic acid (IPA) as a protective metabolite linking restored intestinal tryptophan handling to prevention of diabetic retinopathy in mice and associates low serum IPA with retino

Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment
newsatropineFDA approval

Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia Treatment

By MedXY|Nov 4, 2025

The FDA has rejected Sydnexis’s low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in

Biodegradable Aflibercept Microsphere‑Hydrogel Shows Long‑Term Ocular Biocompatibility in Rhesus Macaques
newsafliberceptophthalmology

Biodegradable Aflibercept Microsphere‑Hydrogel Shows Long‑Term Ocular Biocompatibility in Rhesus Macaques

By MedXY|Nov 3, 2025

A biodegradable PLGA microsphere–thermo‑responsive hydrogel delivering aflibercept was well tolerated after single intravitreal injection in 23 rhesus macaques with preserved retinal structure and function up to 24 months.

Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy
newscenegerminChina

Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy

By MedXY|Nov 2, 2025

A prospective phase IV open‑label Chinese study found cenegermin achieved corneal healing in 84.6% of stage 2/3 neurotrophic keratopathy patients at 8 weeks, with durable effects through 56 weeks and an acceptable safety profile.

Long-Term Progression and Risk Factors of Diabetic Retinopathy in Type 2 Diabetes: Insights from the Skaraborg Cohort in Sweden
Diabetes & Endocrinologycohort studyretinopathy đái tháo đường

Long-Term Progression and Risk Factors of Diabetic Retinopathy in Type 2 Diabetes: Insights from the Skaraborg Cohort in Sweden

By MedXY|Oct 31, 2025

This cohort study tracks diabetic retinopathy incidence over 24 years in type 2 diabetes patients, highlighting the impact of glycemic control and hypertension on disease progression.

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes
Diabetes & Endocrinologydiabetic retinopathyGLP-1 receptor agonists

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes

By MedXY|Oct 29, 2025

GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, war

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults
Diabetes & Endocrinologyage-related macular degenerationGLP-1 receptor agonists

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY|Oct 25, 2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy
Hematology-Oncologygene therapySoft Tissue Sarcoma

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY|Oct 24, 2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Impact of Multifactorial Interventions on Retinopathy in Type 2 Diabetes: Insights from the J-DOIT3 Trial
Diabetes & EndocrinologyHbA1chypoglycemia

Impact of Multifactorial Interventions on Retinopathy in Type 2 Diabetes: Insights from the J-DOIT3 Trial

By MedXY|Oct 24, 2025

This analysis highlights how intensive multifactorial management and glycemic control influence diabetic retinopathy onset, emphasizing the risks associated with hypoglycemia despite good glycemic control.

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence
OphthalmologyalteplaseAspirin

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY|Oct 22, 2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression
Ophthalmologyage-related macular degenerationcohort study

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression

By MedXY|Oct 21, 2025

This review synthesizes current evidence from large cohorts, meta-analyses, and randomized trials evaluating metformin’s association with AMD development and progression, highlighting a nuanced but inconclusive protective potential re

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial
Diabetes & Endocrinologyclinical trialThyroid Eye Disease

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY|Oct 15, 2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Vogt-Koyanagi-Harada Syndrome Presenting with Ophthalmic and Neurological Symptoms: A Case Report
Neurologycase reportdiagnosis

Vogt-Koyanagi-Harada Syndrome Presenting with Ophthalmic and Neurological Symptoms: A Case Report

By MedXY|Oct 5, 2025

A 38-year-old male with bilateral blurred vision and neurological symptoms was diagnosed with Vogt-Koyanagi-Harada syndrome and managed successfully with corticosteroids and immunosuppressants.

Nonmedical Factors Impacting Quality of Care in Newly Diagnosed Primary Open-Angle Glaucoma Patients
Clinical Updatesglaucomahealthcare disparities

Nonmedical Factors Impacting Quality of Care in Newly Diagnosed Primary Open-Angle Glaucoma Patients

By MedXY|Sep 28, 2025

This study reveals that socioeconomic status, residential location, and household composition significantly affect treatment outcomes and follow-up in newly diagnosed POAG patients, highlighting the need for targeted strategies to improve g

Acute Angle Closure Incidence in a Large Countywide Safety Net Teleretinal Screening Program: Safety of Pharmacologic Dilation in Diabetic Retinopathy Screening
Diabetes & Endocrinologydiabetic retinopathy

Acute Angle Closure Incidence in a Large Countywide Safety Net Teleretinal Screening Program: Safety of Pharmacologic Dilation in Diabetic Retinopathy Screening

By MedXY|Sep 28, 2025

This review synthesizes evidence on the incidence of acute angle closure (AAC) following pharmacologic pupillary dilation in a large teleretinal screening program, confirming the very low risk and supporting dilation safety in diverse popul

Understanding Patient Acceptance of Complement Inhibitor Therapy in Geographic Atrophy
OphthalmologyComplement InhibitorsGeographic Atrophy

Understanding Patient Acceptance of Complement Inhibitor Therapy in Geographic Atrophy

By MedXY|Sep 27, 2025

A UK study reveals most patients with geographic atrophy are open to intravitreal complement inhibitor injections if these treatments offer vision improvement, highlighting the vital role of functional benefits in therapy acceptance.

Atropine vs Cyclopentolate: Optimizing Premyopia Diagnosis in Preschool Children
Clinical Updatesatropine

Atropine vs Cyclopentolate: Optimizing Premyopia Diagnosis in Preschool Children

By MedXY|Sep 27, 2025

This study compares atropine and cyclopentolate for cycloplegia in preschoolers, finding atropine leads to less myopic refraction and may reduce premyopia overestimation. It highlights implications for precise refractive diagnosis in young

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema
Clinical UpdatesAnti-VEGF糖尿病黄斑浮腫

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

By MedXY|Sep 17, 2025

A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEG

Prev
13 / 14
1…11121314
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Browse by specialty

Open language-specific specialty feeds and department pages.

news7402 articlesCardiology1459 articlesClinical Updates1386 articlesOncology1266 articlesDiabetes & Endocrinology934 articlesNeurology896 articlesPublic Health645 articlesGastroenterology629 articles
Hematology-Oncology
564 articles
Pediatrics541 articles
Internal Medicine486 articles